Barclays PLC Chinook Therapeutics, Inc. Transaction History

Barclays PLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 03, 2023	BUY	$18.66 - $38.58 $480,140 - $992,701	25,731 Added 30.66%	109,656 $4.21 Million
Q1 2023 May 04, 2023	SELL	$21.53 - $26.8 $387,884 - $482,828	-18,016 Reduced 17.67%	83,925 $1.94 Million
Q4 2022 Feb 13, 2023	BUY	$18.63 - $27.35 $180,152 - $264,474	9,670 Added 10.48%	101,941 $2.67 Million
Q3 2022 Nov 03, 2022	BUY	$17.51 - $23.37 $1.54 Million - $2.06 Million	87,934 Added 2027.53%	92,271 $1.81 Million
Q2 2022 Aug 12, 2022	SELL	$12.59 - $18.8 $51,027 - $76,196	-4,053 Reduced 48.31%	4,337 $75,000
Q1 2022 May 16, 2022	BUY	$12.02 - $16.69 $100,847 - $140,029	8,390 New	8,390 $137,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.